Montelukast Actavis

Montelukast, the active ingredient in Montelukast Actavis, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway disorders. - Asthma: improves control of persistent asthma and reduces exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain: occasional discomfort. - Cough: non‑productive. - Diarrhea: mild episodes. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: including depression or suicidal thoughts. - Allergic reactions: such as angioedema or anaphylaxis. - Hepatotoxicity: elevated liver enzymes. - Severe skin reactions: Stevens‑Johnson syndrome. - Blood dyscrasias: rare cases of neutropenia.

Before initiating therapy, consider the following safety measures. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Breastfeeding: assess benefit‑risk balance before use. - Hepatic impairment: monitor liver function in patients with existing liver disease. - Psychiatric history: observe for mood alterations or suicidal ideation. - Concomitant asthma therapy: do not replace inhaled corticosteroids with Montelukast alone. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may lower Montelukast plasma concentrations. - Rifampin: induces metabolism, potentially reducing therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): monitor for mood changes. - Antihistamines: may increase sedation when combined. - CYP3A4 inhibitors (e.g., ketoconazole): observe for possible increased Montelukast levels.